Cardiovascular Research – Hypertension
Olle Melander’s group
Our research
When type 2 diabetes has been determined, a patient’s absolute risk of future cardiovascular disease events remains very high despite available preventive therapies. Thus, primary prevention of diabetes appears instrumental in reducing the population burden of diabetes-related cardiovascular disease. This group focuses on identifying mechanisms causally related to CVD development in order to provide novel targets for drug discovery and targeted lifestyle interventions for use in primary prevention.
Aims
Our research aims are to identify modifiable metabolic and hormonal disturbances which precede both diabetes and cardiovascular disease development in the population, and develop and test preventive therapies against such metabolic and hormonal disturbances.
Impact
If successful, novel primary preventive therapies may be developed and applied in the personalised medicine environment.
Research output
Link to a list of research output by the group in Lund University’s research portal
Team members
Link to a list of team members in Lund University's research portal
Current major grants
- Advanced grant in life science from European Research Council 2020-2024
Title:Moving from biomarkers to mechanism-oriented prevention of cardiometabolic disease
Link to project description - Project Grant from the Heart and lung foundation 2022-2024
- Project grants in endocrinology and metabolism from Novo Nordisk 2020-2023
Title: Intravascular trapping of the Bio-Active form of adrenomedullin as a novel preventive treatment for diabetes and cardiovascular disease
Olle Melander
Principal Investigator
Professor of internal medicine
+46 704 54 68 20
+46 40 39 12 09
olle [dot] melander [at] med [dot] lu [dot] se
Olle Melander's profile in Lund University research portal
Affiliations
EXODIAB: Excellence of Diabetes Research in Sweden
Link to EXODIAB’s page in Lund University’s research portal
Epihealth: Epidemiology for health